Painkiller PBS listed
A new drug is available on the PBS as a restricted benefit for chronic severe disabling pain unresponsive to non-narcotic analgesics.
Marketed as Palexia SR, tapentadol HCI is the first dual pathway acting MOR-NRI analgesic in a single molecule.
The centrally acting schedule 8 analgesic targets both ascending and descending pain pathways through the complementary actions of MOR and NRI.
Tapentadol HCI has proven effective in managing pain for people with chronic osteoarthritis of the knee and hip, painful diabetic peripheral neuropathy and chronic low back pain with or without a